Form 4: Aclaris Therapeutics Executive James Loerop Reports Stock Transactions

James Loerop, Chief Business Officer of Aclaris Therapeutics, reports the vesting and tax withholding of restricted stock units and the grant of new restricted stock units and stock options.

Summary

• On February 1, 2025, James Loerop, Chief Business Officer of Aclaris Therapeutics, engaged in multiple transactions involving Aclaris Therapeutics common stock and restricted stock units.
• These transactions included the vesting of 11,250, 7,500, and 14,750 restricted stock units, the withholding of 15,447 shares to cover tax obligations at a price of $2.48 per share, and the acquisition of additional restricted stock units.
• On February 3, 2025, Loerop was granted 83,500 restricted stock units and an option to purchase 292,300 shares of common stock.
• The restricted stock units vest in four equal installments on the first, second, third, and fourth anniversaries of the grant date, contingent upon continued service.
• The stock options also vest in four equal installments on the same schedule.
• Following these transactions, Loerop directly owns 103,306 shares of Aclaris Therapeutics common stock, 83,500 restricted stock units that vest beginning February 3, 2025, and an option to purchase 292,300 shares of common stock that vest beginning February 3, 2025.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to executive compensation. It doesn't contain information that would significantly shift investor sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in stock transactions by company insiders. This filing provides insight into the compensation structure and equity ownership of Aclaris Therapeutics' executives.

Stakeholder Impact

• Shareholders may be interested in the equity-based compensation of key executives.
• Employees may be interested in the equity-based compensation of key executives.

Key Dates